DK0939765T3 - Glycokonjugater af modificerede camptothecin-derivater (A- eller B-ringbinding) - Google Patents
Glycokonjugater af modificerede camptothecin-derivater (A- eller B-ringbinding)Info
- Publication number
- DK0939765T3 DK0939765T3 DK97910297T DK97910297T DK0939765T3 DK 0939765 T3 DK0939765 T3 DK 0939765T3 DK 97910297 T DK97910297 T DK 97910297T DK 97910297 T DK97910297 T DK 97910297T DK 0939765 T3 DK0939765 T3 DK 0939765T3
- Authority
- DK
- Denmark
- Prior art keywords
- pct
- glycoconjugates
- camptothecin derivatives
- ring binding
- modified camptothecin
- Prior art date
Links
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
- C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19640207A DE19640207A1 (de) | 1996-09-30 | 1996-09-30 | Glycokonjugate von modifizierten Camptothecin-Derivaten (A- oder B-Ring-Verknüpfung) |
| PCT/EP1997/005089 WO1998014468A1 (de) | 1996-09-30 | 1997-09-17 | Glycokonjugate von modifizierten camptothecin-derivaten(a- oder b-ring-verknüpfung) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0939765T3 true DK0939765T3 (da) | 2002-04-02 |
Family
ID=7807374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK97910297T DK0939765T3 (da) | 1996-09-30 | 1997-09-17 | Glycokonjugater af modificerede camptothecin-derivater (A- eller B-ringbinding) |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6156754A (da) |
| EP (1) | EP0939765B1 (da) |
| JP (1) | JP2001506232A (da) |
| AT (1) | ATE210147T1 (da) |
| AU (1) | AU4774897A (da) |
| CA (1) | CA2267493A1 (da) |
| DE (2) | DE19640207A1 (da) |
| DK (1) | DK0939765T3 (da) |
| ES (1) | ES2169362T3 (da) |
| PT (1) | PT939765E (da) |
| WO (1) | WO1998014468A1 (da) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7244701B2 (en) * | 2000-06-16 | 2007-07-17 | Zealand Phama A/S | Diuretic peptide conjugate |
| US7550425B2 (en) * | 2000-06-16 | 2009-06-23 | Zealand Pharma A/S | Diuretic peptide conjugates |
| US8435529B2 (en) | 2002-06-14 | 2013-05-07 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
| US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
| US8420086B2 (en) | 2002-12-13 | 2013-04-16 | Immunomedics, Inc. | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases |
| US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
| EP3912643B8 (en) | 2009-02-13 | 2023-08-23 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
| US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| US10744129B2 (en) | 2012-12-13 | 2020-08-18 | Immunomedics, Inc. | Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 |
| US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
| US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
| WO2015012904A2 (en) | 2012-12-13 | 2015-01-29 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
| US10206918B2 (en) | 2012-12-13 | 2019-02-19 | Immunomedics, Inc. | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers |
| US20240139324A1 (en) | 2012-12-13 | 2024-05-02 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity |
| US12310958B2 (en) | 2012-12-13 | 2025-05-27 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| US10413539B2 (en) | 2012-12-13 | 2019-09-17 | Immunomedics, Inc. | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) |
| SI2900277T1 (sl) | 2012-12-13 | 2022-05-31 | Immunomedics, Inc. | Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost |
| US11253606B2 (en) | 2013-07-23 | 2022-02-22 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| WO2016172427A1 (en) | 2015-04-22 | 2016-10-27 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
| KR101639160B1 (ko) * | 2015-06-10 | 2016-07-12 | 건국대학교 산학협력단 | 메틸 바이올렛 염료 제거용 벤질 트리아졸 덱스트란 유도체 |
| US10195175B2 (en) | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
| CN115969970A (zh) | 2016-02-10 | 2023-04-18 | 免疫医疗公司 | Abcg2抑制剂与sacituzumab govitecan的组合 |
| JP7379795B2 (ja) | 2016-04-27 | 2023-11-15 | イミューノメディクス、インコーポレイテッド | チェックポイント阻害薬に再発／耐性を示す腫瘍を治療するための抗Ｔｒｏｐ－２－ＳＮ－３８抗体薬物複合体の効果 |
| US10918734B2 (en) | 2017-03-27 | 2021-02-16 | Immunomedics, Inc. | Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51 |
| WO2018187074A1 (en) | 2017-04-03 | 2018-10-11 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| JP7561141B2 (ja) * | 2019-04-26 | 2024-10-03 | イミュノジェン・インコーポレーテッド | カンプトテシン誘導体 |
| US20230416270A1 (en) * | 2020-12-11 | 2023-12-28 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Novel camptothecin derivative, composition comprising same and use thereof |
| TW202547842A (zh) | 2021-04-29 | 2025-12-16 | 愛爾蘭商艾伯維製造管理無限公司 | 抗c-Met抗體藥物結合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5340817A (en) * | 1987-04-14 | 1994-08-23 | Research Triangle Institute | Method of treating tumors with anti-tumor effective camptothecin compounds |
| US4943579A (en) * | 1987-10-06 | 1990-07-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble prodrugs of camptothecin |
| NZ235329A (en) * | 1989-09-15 | 1992-01-29 | Res Triangle Inst | 20(s or rs)-camptothecin derivatives and pharmaceutical compositions |
| EP0556585A3 (en) * | 1992-01-24 | 1993-09-01 | Takeda Chemical Industries, Ltd. | Condensed camptothecin derivatives their production and use as antitumor agents |
| DE4236237A1 (de) * | 1992-10-27 | 1994-04-28 | Behringwerke Ag | Prodrugs, ihre Herstellung und Verwendung als Arzneimittel |
| EP0640622B1 (en) * | 1993-02-26 | 2000-08-09 | Drug Delivery System Institute, Ltd. | Polysaccharide derivative and drug carrier |
| US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5646159A (en) * | 1994-07-20 | 1997-07-08 | Research Triangle Institute | Water-soluble esters of camptothecin compounds |
| SG50747A1 (en) * | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| CA2192725C (en) * | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
-
1996
- 1996-09-30 DE DE19640207A patent/DE19640207A1/de not_active Withdrawn
-
1997
- 1997-09-17 CA CA002267493A patent/CA2267493A1/en not_active Abandoned
- 1997-09-17 DK DK97910297T patent/DK0939765T3/da active
- 1997-09-17 WO PCT/EP1997/005089 patent/WO1998014468A1/de not_active Ceased
- 1997-09-17 EP EP97910297A patent/EP0939765B1/de not_active Expired - Lifetime
- 1997-09-17 AU AU47748/97A patent/AU4774897A/en not_active Abandoned
- 1997-09-17 PT PT97910297T patent/PT939765E/pt unknown
- 1997-09-17 JP JP51618298A patent/JP2001506232A/ja active Pending
- 1997-09-17 US US09/269,314 patent/US6156754A/en not_active Expired - Fee Related
- 1997-09-17 AT AT97910297T patent/ATE210147T1/de not_active IP Right Cessation
- 1997-09-17 ES ES97910297T patent/ES2169362T3/es not_active Expired - Lifetime
- 1997-09-17 DE DE59705710T patent/DE59705710D1/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE210147T1 (de) | 2001-12-15 |
| EP0939765B1 (de) | 2001-12-05 |
| DE59705710D1 (de) | 2002-01-17 |
| AU4774897A (en) | 1998-04-24 |
| US6156754A (en) | 2000-12-05 |
| PT939765E (pt) | 2002-05-31 |
| WO1998014468A1 (de) | 1998-04-09 |
| JP2001506232A (ja) | 2001-05-15 |
| EP0939765A1 (de) | 1999-09-08 |
| DE19640207A1 (de) | 1998-04-02 |
| ES2169362T3 (es) | 2002-07-01 |
| CA2267493A1 (en) | 1998-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0939765T3 (da) | Glycokonjugater af modificerede camptothecin-derivater (A- eller B-ringbinding) | |
| MX9700885A (es) | Nuevas heteroariloxazolidinonas. | |
| BG102616A (en) | Substituted aza- and diazacycloheptane and cyclooctane derivatives and their application | |
| EE200000320A (et) | Uudsed ühendid | |
| SE9704544D0 (sv) | Novel compounds | |
| CR6540A (es) | Trifluorobutenos nematicidas | |
| NO931635D0 (no) | Fremgangsmaate for fremstilling av kinazolin-derivater | |
| BG104812A (en) | New dihydropyrimidines | |
| BG103251A (bg) | Оксадиазоли, методи за получаването им и приложението им като лекарствени средства | |
| MD1838G2 (ro) | Derivaţi de 5,6-diclorbenzimidazol, procedeu de obţinere a lor, compoziţie farmaceutică şi metodă de tratament sau de prevenire a infecţiei virotice herpetice | |
| DK0584136T3 (da) | Bestemmelse af peptidmotiver på MHC-molekyler | |
| DE69532580D1 (de) | Neue antagonistische verbindungen | |
| DK0934329T3 (da) | Glycokonjugater af modificerede camptothecinderivater (20-O-binding) | |
| TR199900501T2 (xx) | Benzamin t�revleri ve bunlar�n ila� olarak kullan�m�. | |
| EE03526B1 (et) | Leukotrieen-antagonistliku toimega bensopüraanderivaadid, nende valmistamismeetod ja kasutamine | |
| TR199801328T2 (xx) | Yeni tarz benzoilguanidin-t�revleri, �retim y�ntemleri. | |
| BG104291A (en) | 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use | |
| MY120550A (en) | Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions. | |
| KR930702004A (ko) | 세파로스포란 산 유도체를 함유하는 정제를 제조하기 위한 직접 압축 방법 | |
| NZ210914A (en) | 4,6,6a,7,8,12b-hexahydroindolo(4,3-ab)phenanthridine,derivatives thereof and pharmaceutical compositions | |
| DK0809627T3 (da) | Hidtil ukendte borneolderivater, fremgangsmåde til deres fremstilling og deres farmaceutiske anvendelse | |
| SE9803107D0 (sv) | Novel Compunds | |
| DE69527630D1 (de) | Wasserlösliche glykolisierte derivate von 1,2-dithiinverbindungen | |
| DE60039122D1 (de) | 6-o-alkyl-2-nor-2-substituierte ketolidderivate | |
| DE69627184D1 (de) | 3-aminoethyl-n-amidino-2,5-dihydropyrrol derivative mit arginine-mimetischen eigenschaften |